Drugs / ALVAC gp100 Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00610311 | Jan 2008 → Feb 2011 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC gp100 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00610311 ↗ |
| Route | Subcutaneous | “gp100 ALVAC virus subcutaneously in each extremity” NCT00610311 ↗ |